Market Research Report
Product Strategies for Non-Oral Hematology Drugs
|Published by||Greystone Research Associates||Product code||243430|
Delivery time: 1-2 business days
|Product Strategies for Non-Oral Hematology Drugs|
|Published: June 4, 2012||Content info:||
This publication has been discontinued on July 21, 2015.
Greystone Research Associates is pleased to announce the publication of a new market study. Product Strategies for Non-Oral Hematology Drugs is a comprehensive analysis of the technology, products and participants that comprise this segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug developers, formulation specialists, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and strategic opportunities for non-oral hematology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The administration of non-oral drugs for the treatment of blood disorders has evolved over the past ten years to include heparin analogs and recombinant proteins designed to treat chronic conditions that are life threatening and often debilitating illnesses. As the availability of drugs based on new APIs or molecular entities has grown, the product strategies in the marketplace have increased in specificity and sophistication. The chronic nature of many blood diseases and the growing trend toward patient self-administration for non-oral medications is requiring drug developers and product managers to refine their product strategy at the highest level, with formulation and device selection decisions being made prior to the clinical trial phase of development.
The result has been greater reliance on concurrent product development processes and stronger partnerships between drug companies and device designers. Formulations that can extend the half-life of hematology drugs are also gaining traction, as developers strive to create drugs with lower dosing frequencies as a way to improve patient safety and compliance. These factors are combining to make hematology drug product strategies more complex and multi-faceted, and challenging managers to think and react well beyond traditional drug development models.